Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA2 | P00918 | 11/20 | 0.44 |
| ▸ | CA12 | O43570 | 9/20 | 0.44 |
| ▸ | CA9 | Q16790 | 7/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22829019 | 0.89 | TDP1 (0.57) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL34474320 | 0.88 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL34467716 | 0.84 | CA1 (0.45) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL5213233 | 0.83 | TDP1 (0.53) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7352046 | 0.83 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL30803605 | 0.82 | TDP1 (0.46) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL18970801 | 0.81 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL5209649 | 0.81 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL29948784 | 0.81 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL27093248 | 0.81 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232036-A | Stilbene polyphenol taurate, preparation method and application thereof | 南通大学 | 2022-10-25 | — | — | CN | claimed |
| CN-115160192-A | 2-guanidinoethane-1-sulfonic acid dioctadecyl ester, preparation method and application thereof | 南通大学 | 2022-10-11 | — | — | CN | claimed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025021118-A9 | LIGAND-DRUG CONJUGATE AND LINKER FOR CONJUGATION | 海南先声再明医药股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| WO-2025040569-A1 | 1,3-DIHYDRO-2H-PYRROLO[3,4-C]QUINOLINE DERIVATIVES AS CGAS INHIBITORS FOR THE TREATMENT OF INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025021118-A1 | LIGAND-DRUG CONJUGATE AND LINKER FOR CONJUGATION | 海南先声再明医药股份有限公司 | 2025-01-30 | — | — | WO | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2020256544-A1 | TETRAZINES FOR HIGH CLICK RELEASE SPEED AND YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2020-12-24 | — | — | WO | disclosed |
| US-10196411-B2 | Tizoxanide phosphate and alkane sulfonate and pharmaceutical applications thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2019-02-05 | — | — | US | disclosed |
| US-20170362261-A1 | Tizoxanide Phosphate and Alkane Sulfonate and Pharmaceutical Applications Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-12-21 | — | — | US | disclosed |
| US-20170362261-A1 | Tizoxanide Phosphate and Alkane Sulfonate and Pharmaceutical Applications Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2017-12-21 | — | — | US | disclosed |
| EP-3239160-A1 | TIZOXANIDE PHOSPHATE AND ALKANE SULFONATE AND PHARMACEUTICAL APPLICATIONS THEREOF | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2017-11-01 | — | — | EP | disclosed |
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
| WO-2003024923-A1 | SULFONAMIDE COMPOUNDS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | TDP1 4502/4885MEN1 369/4885GAA 1806/4885 |
| US-10196411-B2 | Tizoxanide phosphate and alkane sulfonate and pharmaceutical applications thereof | TPI1, ALK, STS | TDP1 904/4885MEN1 4147/4885GAA 426/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | TDP1 4502/4885MEN1 369/4885GAA 1806/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | TDP1 3871/4885MEN1 744/4885GAA 1115/4885 |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | TDP1 2953/4885MEN1 4533/4885GAA 393/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | TDP1 2438/4885MEN1 4295/4885GAA 4213/4885 |
| US-20170362261-A1 | Tizoxanide Phosphate and Alkane Sulfonate and Pharmaceutical Applications Thereof | TPI1, ALK, STS | TDP1 904/4885MEN1 4147/4885GAA 426/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | TDP1 3735/4885MEN1 380/4885GAA 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.